Education
About Us
Working with TipRanks
Follow Us
Kairos Pharma, Ltd. (KAPA)
:KAPA
See the Price Targets and Ratings of:
KAPA Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Maxim Group
$4
Buy
601.75%
Upside
Reiterated
11/18/25
H.C. Wainwright
$12
Buy
2005.26%
Upside
Reiterated
09/22/25
Promising Phase 2 Results and Safety Profile of ENV-105 Bolster Buy Rating for Kairos PharmaValuation and Risks. We reiterate our Buy rating and $12 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's profile.
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Maxim Group
$4
Buy
601.75%
Upside
Reiterated
11/18/25
H.C. Wainwright
$12
Buy
2005.26%
Upside
Reiterated
09/22/25
Promising Phase 2 Results and Safety Profile of ENV-105 Bolster Buy Rating for Kairos PharmaValuation and Risks. We reiterate our Buy rating and $12 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's profile.
Best Analysts Covering Kairos Pharma, Ltd.
3 Months
xxx
Success Rate
2/7 ratings generated profit
Average Return
+7.29%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 28.57% of your transactions generating a profit, with an average return of +7.29% per trade.
1 Year
Success Rate
1/7 ratings generated profit
Average Return
-38.64%
reiterated a buy rating 3 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -38.64% per trade.
2 Years
xxx
Success Rate
1/7 ratings generated profit
Average Return
-38.64%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 14.29% of your transactions generating a profit, with an average return of -38.64% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
KAPA Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
5
5
6
5
4
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
5
6
5
4
Each month's total comprises the sum of three months' worth of ratings.
KAPA Stock Forecast FAQ
What is KAPA’s average 12-month price target, according to analysts?
Currently, no data Available
What is KAPA’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for KAPA, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KAPA a Buy, Sell or Hold?
Kairos Pharma, Ltd. has a consensus rating of Moderate Buy which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is Kairos Pharma, Ltd.’s price target?
Currently, no data Available
What do analysts say about Kairos Pharma, Ltd.?
Kairos Pharma, Ltd.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of KAPA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.